Remove Access Remove Cannabinoids Remove Pharmaceutical
article thumbnail

Clinical Trial: Cannabinoid Administration Via a Metered-Dose Inhaler Is Safe and Effective for Chronic Pain Patients

NORML

Thus, it enables individualization of medical cannabis regimens that can be evaluated pharmacokinetically and pharmacodynamically by accepted pharmaceutical models.” Chronic pain is the most commonly reported qualifying condition among medical cannabis patients enrolled in state-specific access programs.

article thumbnail

Expert Gives Delta-8 THC Thumbs Down

Project CBD

Project CBD: Your presentation with Allyn Howlett at the International Cannabinoid Research Society conference in Toronto (June 2023) discussed the chemical conversion of CBD into Δ8-THC (delta-8 THC) and “numerous additional THC isomers. At issue are potent, intoxicating cannabinoids other than cannabis-derived Δ9-THC.

THC 212
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

Cannabis Law Report

We are delighted by today’s decision from the MHRA for this new indication, which represents a significant step forward for TSC patients in the UK, many of whom may benefit from this new treatment,” said Chris Tovey , Executive Vice President, Chief Operating Officer and Managing Director, Europe & International at Jazz Pharmaceuticals.

article thumbnail

States That Restrict MMJ Access Are Interfering With Patients’ Rights, Study Shows

Veriheal

As medicinal and recreational cannabis legalization continues to sweep across the United States, a recent study paints a concerning portrait of many states denying or restricting medical marijuana (MMJ) access. Nugg MD’s report suggests there is more to unpack when analyzing healthcare disparities related to MMJ access.

Access 98
article thumbnail

Serious Conditions Are Responding To Cannabinoid Therapy

Peninsula Alternative Health

Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. However, because cannabinoids reduce seizures through numerous mechanisms of actions, possible drug interactions are still unclear.

article thumbnail

Curaleaf International Advances Accessibility of Medical Cannabis Products in Germany with Strategic Partnership

Cannabis Law Report

Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. Zambon is a multinational pharmaceutical company that focuses on innovation and development with the aim to improve patients’ lives. The market for medical cannabis in Germany.

Access 105
article thumbnail

Cannassure was granted a patent for an oral delivery method of cannabis and cannabinoids compositions by the Israel Patents Authority

Cannabis Law Report

Cannassure Therapeutics Ltd (TASE: CSURE) (“Cannassure”), an Israel based developer and producer of innovative medical cannabis products, announces today that the company was granted a patent for an oral delivery method of cannabis and cannabinoids compositions by the Israel Patents Authority. Of Cannassure.